Cornea - ARVO

More documents

Recommendations

Info

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Corneasessions during which hydrogel contact lenses were fitted to botheyes and a fluorescein solution was applied in one of three ways toone eye only; directly onto the IEL, OEL, or via a liposomal spray tothe closed lid. The lenses were harvested after 20 minutes andexamined using UV spectrophotometry. Differences in UVabsorbance over 400-600nm indicated fluorescein uptake comparedto control lenses.Results: Part 1: A significant change in the lipid layer pattern of thetear film was observed after five minutes for IEL (p=0.007), but notuntil 20 minutes for OEL (p=0.037). Tear film stability decreasedsignificantly within five minutes for IEL application (p=0.010), butnot until 20 min for OEL (p=0.045).Part 2: Contact lenses harvested after IEL application demonstratedsignificantly greater absorbance compared to control lenses(p=0.005). Where fluorescein was applied via spray or OEL, nosignificant difference in absorbance compared to controls wasobserved (p=0.098 and p=0.124, respectively). Comparing theapplication methods, absorbance following IEL was significantlyincreased compared to OEL (p=0.014) and spray (p=0.044).Conclusions: Lipid-based, water-based and liposomal solutions canmigrate across the muco-cutaneous junction when applied in closeproximity to the eye. All three applications studied showed somemigration; however application to the IEL was found to be mosteffective in allowing for migration into the tear film. Application of alipid based solution to the IEL exhibited migration that was 4 timesfaster than OEL application. This has implications for drug deliveryand cosmetic use around the eyelid margins.Commercial Relationships: Christine Purslow, None; ClareConaty, None; Alison Ng, None139 Ocular Surface and Tear FilmSunday, May 05, 2013 1:00 PM-2:45 PMExhibit Hall Poster SessionProgram #/Board # Range: 955-978/B0260-B0283Organizing Section: CorneaProgram Number: 955 Poster Board Number: B0260Presentation Time: 1:00 PM - 2:45 PMTear Film Biomarker Profiling of Subjects with Dry Eye Diseaseby Multiplex AnalysisSuzanne Hagan 1, 2 , Alan Tomlinson 1 , Louise Madden 1 , Anne MarieClark 2 , Katherine M. Oliver 1 . 1 Vision Sciences, Glasgow CaledonianUniversity, Glasgow, United Kingdom; 2 Biological and BiomedicalSciences, Glasgow Caledonian University, Glasgow, UnitedKingdom.Purpose: Dry eye disease (DED) is a distressing disorder, commonlyassociated with ageing, contact lens wear and autoimmunesyndromes. It affects 15%-30% of the over-50s in Western and Asianpopulations and is one of the fastest-growing eye problems in thisdemographic. DED is significantly underdiagnosed and no “goldstandard” currently exists for its clinical diagnosis. Recent Multiplexstudies of tear fluids from DED subjects have implicatedinflammatory cytokines in this disorder. In this study, we investigatedtear fluids from DED and normal subjects for a panel of cytokinesusing the multiplex bead assay.Methods: This study comprised 15 DED subjects (3 males, 12females) and 20 healthy controls (2 males, 18 females). All subjectsprovided informed consent and the study adhered to the Declarationof Helsinki tenets. Tear samples were collected from the externalcanthus of open eyes, avoiding additional tear reflex. Glassmicrocaps were used to collect 1μl tears. Samples were diluted 1:50and stored at -80C until use. Tear cytokine levels were determinedwith a multiplex bead assay (R and D Systems) and quantified usinga Luminex IS200. Briefly, tear samples were incubated with specificantibody-coated beads for 3h. Washed beads were then incubatedwith biotin-labelled secondary antibodies, followed by a streptavidin-PE incubation. Standard curves of known cytokine concentrationswere used to calculate protein concentrations and data underwentanalysis by an in-house statistician.Results: Detectable levels of IL-8 (> 4.05pg/ml) were observed in12/15 DED subjects (mean 23.1pg/ml) and 16/19 normals (mean20.6pg/ml). Some variation in IL-8 levels was noted in DED subjects(4.9-83.8pg/ml), but a trend for increased IL8 in DED subjects wasobserved, compared to normals. Moreover, detectable levels of all 7inflammatory proteins (IL1β, IL2, IL6, IL8, IL17, TNF-α and IFN-γ)were observed in 2 DED subjects, a result not observed in normals.Conclusions: Increased IL8 levels in DED suggests a function inocular surface inflammation. This data confirms previous Multiplexbead studies, indicating a role for IL8 in DED. Further studies mayalso shed light on roles for the other 6 cytokines detected in 2 DEDsubjects. Moreover, this technology appears to be sensitive enough todetect low abundance proteins in minute sample sizes and thereforemay be useful in screening tear fluids for potential biomarkers ofDED.Commercial Relationships: Suzanne Hagan, Allergan (F); AlanTomlinson, Allergan (E), Allergan (R), Bausch and Lomb (C),TearLab (C), TearLab (I), Alcon, CibaVision (C), Pfizer (R), Pfizer(C); Louise Madden, None; Anne Marie Clark, None; KatherineM. Oliver, Allergan (F)Program Number: 956 Poster Board Number: B0261Presentation Time: 1:00 PM - 2:45 PMDouble rows of meibomian gland orifices observed by noninvasiveinfrared meibographyRika Shirakawa 1 , Reiko Arita 1, 2 , Shima Fukuoka 1, 3 , SatoshiYamamoto 4 , Kaori Yonehara 4 , Tsuyoshi Haraguchi 4 , Shiro Amano 1 .1 Ophthalmology, University of Tokyo, Tokyo, Japan;2 Ophthalmology, Itoh Clinic, Tokyo, Japan; 3 Ophthalmology, ToyoKyosai Hospital, Tokyo, Japan; 4 Topcon Corporation, Tokyo, Japan.Purpose: Multiple rows of meibomian gland orifices (MGOs), whichwere first reported in 1992 by Hykin and Bron, exist mainly in theupper eyelids of young people. Little is known about the morphologyof the meibomian glands and their influences on the ocular surface.We observed lid margins and meibomian glands in healthy youngadults to explore the incidence, morphology and function of doublerows of MGOs.Methods: Subjects were consecutive cases of healthy malevolunteers under 36 years of age. After obtaining written consent, wemeasured the width of the eyelid, counted the number of MGOs inthe upper and lower eyelids, obtained a fluorescein staining score,tear break-up time (BUT), meibum expressibility grade, tearmeniscus height under the slit-lamp microscopy, and performed aSchirmer tear production test. We also recorded images ofmeibomian glands by non-invasive infrared meibography, whichwere later reviewed to count the number of meibomian glands in eachlid. We scored a meiboscore (grade 0-3) according to the ratio of thearea of missing glands. “Double rows” were defined where more than4 orifices were aligned in a second row distinctly separate from theprimary row. This study was approved by the institutional reviewboard of University of Tokyo School of Medicine, and adhered to thetenets of the Declaration of Helsinki.Results: We examined 35 eyes of 35 people (all male, average age28.9±2.8). We observed double rows of MGOs in the upper eyelidsof 10 eyes (28.5%), whereas none (0%) were observed in the lowereyelids. Comparing between the double rows group (n=10) and the©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.
ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Corneasingle row group (n=25), the number of the orifices and number ofthe meibomian glands in the upper eyelids are significantly higher inthe double rows group (48.0±5.7 vs 36.3±4.9, p6 hours after a singledose. In the IL-1 mouse and ExLac rat models of dry eye disease,treatment with ENaC blockers significantly improved tear volumeand corneal fluorescein staining.Conclusions: Our studies demonstrate that ENaC inhibitors providelong-acting increases in tear volume and that restoring volume aloneis sufficient to provide significant improvements in ocular surfacehealth in models of dry eye disease. Our data provide a clear rationalefor the development of ENaC blockers to treat the underlying ocularsurface desiccation in dry eye disease.Commercial Relationships: William Thelin, Parion Sciences (E);M. Ross Johnson, Parion Sciences (I), Parion Sciences (E), ParionSciences (S); John Ansede, Parion Sciences (E); Karl Donn, ParionSciences (E); Dongfang Yu, Parion Sciences (F); Barbara Grubb,©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the ARVO Office at arvo@arvo.org.
Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
Page 4 and 5:
Page 6 and 7:
Page 8 and 9: ARVO 2013 Annual Meeting Abstracts
Page 10: ARVO 2013 Annual Meeting Abstracts
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
show all

Cornea - ARVO

Create successful ePaper yourself

Delete template?

Save as template?